| General Information | |
|---|---|
| ZINC ID | ZINC000043059111 |
| Molecular Weight (Da) | 398 |
| SMILES | CCCCCn1cc(C(=O)c2ccc(CCCC)c3ccccc23)c2ccccc21 |
| Molecular Formula | C28N1O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 124.266 |
| HBA | 1 |
| HBD | 0 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 30 |
| LogP | 8.054 |
| Activity (Ki) in nM | 14.1254 |
| Polar Surface Area (PSA) | 22 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.113 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 19 |
| Fraction csp3 | 0.32 |
| Ilogp | 4.75 |
| Xlogp3 | 8.2 |
| Wlogp | 7.56 |
| Mlogp | 5 |
| Silicos-it log p | 7.72 |
| Consensus log p | 6.65 |
| Esol log s | -7.35 |
| Esol solubility (mg/ml) | 0.0000179 |
| Esol solubility (mol/l) | 4.51E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.52 |
| Ali solubility (mg/ml) | 0.00000119 |
| Ali solubility (mol/l) | 0 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.13 |
| Silicos-it solubility (mg/ml) | 2.94E-08 |
| Silicos-it solubility (mol/l) | 7.40E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -2.9 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 2.98 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.53 |
| Logd | 5.543 |
| Logp | 7.715 |
| F (20%) | 0.805 |
| F (30%) | 0.997 |
| Mdck | - |
| Ppb | 99.23% |
| Vdss | 1.291 |
| Fu | 0.34% |
| Cyp1a2-inh | 0.612 |
| Cyp1a2-sub | 0.205 |
| Cyp2c19-inh | 0.627 |
| Cyp2c19-sub | 0.062 |
| Cl | 4.665 |
| T12 | 0.006 |
| H-ht | 0.09 |
| Dili | 0.916 |
| Roa | 0.181 |
| Fdamdd | 0.457 |
| Skinsen | 0.629 |
| Ec | 0.003 |
| Ei | 0.94 |
| Respiratory | 0.133 |
| Bcf | 1.454 |
| Igc50 | 5.692 |
| Lc50 | 6.202 |
| Lc50dm | 6.65 |
| Nr-ar | 0.034 |
| Nr-ar-lbd | 0.006 |
| Nr-ahr | 0.669 |
| Nr-aromatase | 0.891 |
| Nr-er | 0.74 |
| Nr-er-lbd | 0.744 |
| Nr-ppar-gamma | 0.03 |
| Sr-are | 0.884 |
| Sr-atad5 | 0.4 |
| Sr-hse | 0.28 |
| Sr-mmp | 0.873 |
| Sr-p53 | 0.321 |
| Vol | 452.041 |
| Dense | 0.879 |
| Flex | 0.409 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 4 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.211 |
| Synth | 2.195 |
| Fsp3 | 0.321 |
| Mce-18 | 21 |
| Natural product-likeness | -0.652 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |